Additionally, other tumor microenvironment-related biomarkers like IFN-γ signaling, tumor mutational burden, and microsatellite instability, which were not assessed in this patient, could also affect the antitumor efficacy of anti-PD-1 treatment (22). This evidence concerns the gene IFNG and neoplasm.